ArticleJournal of acquired immune deficiency syndromes (1999)2020

Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).

Diana F Clarke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.